Comparative Evaluation of 11 Prognostic Scores for Atrial Fibrillation Recurrence After Pulmonary Vein Isolation in Non-Paroxysmal AF: A Retrospective Comparative Analysis

11种预后评分对非阵发性房颤患者肺静脉隔离术后房颤复发的预测价值的比较评价:一项回顾性比较分析

阅读:1

Abstract

OBJECTIVE: Pulmonary vein isolation (PVI) remains the cornerstone of catheter ablation for atrial fibrillation (AF); however, a substantial proportion of patients with non-paroxysmal AF (non-PAF) experience recurrence following ablation. With numerous prognostic models available to predict recurrence, the aim of this study is to compare the predictive performance of multiple scoring systems in patients with non-PAF undergoing PVI as a standalone procedure. METHODS: A retrospective analysis was conducted involving 166 patients with non-PAF (22.3% female; mean age 60 ± 9 years) who underwent initial PVI alone. Clinical data, including transthoracic echocardiography and either cardiac computed tomography or transesophageal echocardiography, were collected. The evaluated prognostic scoring systems included APPLE, BASE-AF(2), C(2)HEST, CAAP-AF, CHA(2)DS(2)-VASc, CHADS(2), DR-FLASH, HATCH, MB-LATER, PAT(2)C(2)H, and SCALE-CryoAF. RESULTS: Recurrence of AF following a 90-day blanking period was observed in 41 individuals (24.7%), including 24 (51.8%) in the cryo-balloon ablation (CBA) subgroup and 17 (48.2%) in the radiofrequency catheter ablation (RFCA) subgroup. Among the evaluated models, BASE-AF(2) (AUC = 0.666, 95% CI: 0.572-0.759, p = 0.001), MB-LATER (AUC = 0.734, 95% CI: 0.646-0.821, p < 0.001), and SCALE-CryoAF (AUC = 0.702, 95% CI: 0.600-0.804, p < 0.001) demonstrated superior prognostic performance for recurrence. After propensity score matching, MB-LATER (AUC = 0.734, 95% CI: 0.570-0.899, p = 0.019) was identified as the most effective predictor of recurrence in the CBA subgroup, while BASE-AF(2) (AUC = 0.758, 95% CI: 0.578-0.937, p = 0.013) indicated superior predictive accuracy in the RFCA subgroup. CONCLUSION: The BASE-AF2, MB-LATER, and SCALE-CryoAF scoring systems demonstrated enhanced prognostic use for predicting AF recurrence following PVI alone in patients with non-PAF. MB-LATER exhibited superior performance in those treated with CBA, while BASE-AF2 was more predictive for those who underwent RFCA.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。